ViiV Healthcare presents GEMINI 1 & 2 studies through Week 96 showing 2-drug regimen of dolutegravir plus lamivudine continues to demonstrate high efficacy rates and no cases of treatment emergent resistance - Argus Press

ViiV Healthcare presents GEMINI 1 & 2 studies through Week 96 showing 2-drug regimen of dolutegravir plus lamivudine continues to demonstrate high efficacy rates and no cases of treatment emergent resistance  Argus Press

LONDON--(BUSINESS WIRE)--Jul 24, 2019--. ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited ...



Comments

Popular posts from this blog

The Best Flea Treatments for Cats and Dogs

Everything You Need to Know About Mite and Flea Bites

Is Citronella Safe for Dogs? A Veterinarian Provides Guidance